Pharmacy verification
Compounding Pharmacy Recalls and Warning Letters
FDA warning letters, recall notices and state board disciplinary actions are all public records. Search the pharmacy's name against each before ordering. The FDA has issued warning letters to compounders and telehealth distributors over GLP-1 marketing claims, including claims that compounded products are identical to branded drugs.
Three public records worth searching
FDA warning letters. Published by the agency, naming the recipient and describing the alleged violations. In this category they have addressed marketing claims — including claims that compounded GLP-1s are identical to approved products — as well as manufacturing and quality issues.
Recall notices. Also published, and specific to affected lots. Sterility lapses at compounding facilities have produced recalls in this market.
State board disciplinary actions. Held by each state board of pharmacy, reachable through the NABP directory. These cover licensure conditions, suspensions and revocations.
How to search
- Search the pharmacy's name, not the telehealth brand. The brand on the website is often not the entity that received the letter.
- Search the corporate parent as well, where you can identify it.
- Check the state board in the pharmacy's operating state and in your own.
- Note the date. An old letter that has been resolved is different information from a current one.
What a warning letter means, and what it does not
A warning letter states the agency's position that a violation occurred. It is not a court finding, and recipients frequently respond and remediate. Finding one is a reason to ask questions rather than an automatic disqualification.
What matters more than the existence of a letter is its subject and its recency. A letter about marketing language is a different signal from one about sterility failures, and a resolved issue from 2023 is different from an open one from this year.
The marketing claims that have drawn enforcement
Several are common enough that you may have seen them: that a compounded product is identical to, or a generic version of, an approved drug; that it is FDA-approved; or that trial results for the approved product apply to the compounded one.
All three are inaccurate. There is no generic tirzepatide or semaglutide, no compounded product is FDA-approved, and the trials studied approved subcutaneous injections at studied doses. A provider using this language is telling you something about its compliance posture as well as about its product.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Claim | Proves | Does not prove |
|---|---|---|
| FDA-registered outsourcing facility | A registration was filed | That any product is FDA-approved |
| State pharmacy licence | A board issued a licence | That it is current — check it |
| Accreditation | A voluntary assessment was passed | Batch quality or product approval |
| USP <797> compliance | A sterile compounding standard is claimed | That it was independently audited |
| Third-party tested | Something was tested | What, by whom, or how often, without a certificate |
| NPI number | Identity in a national registry | A current licence in any state |
| FDA-approved compounded medicine | Nothing — the category does not exist | Treat as a red flag |
Providers publishing terms openly are easier to hold to a written answer. NexLife states its pricing and dose-coverage on its own plan pages before intake, which is why its records are the six we marked verified — though it has not named its fulfilling pharmacy to us either. Its published plans.
Questions readers actually ask
Where can I check for warning letters?
The FDA publishes them. Search the pharmacy's own name rather than the telehealth brand, and check state board disciplinary records separately.
Does a warning letter mean I should avoid a provider?
Not automatically. It is a reason to ask what it concerned, when, and what was done about it. Subject and recency matter more than existence.
Related on this site
- Pharmacy verification centrePharmacies
- How to Verify a Compounding PharmacyPharmacies
- 503A Compounding Pharmacy DirectoryPharmacies
- 503B Outsourcing Facility DirectoryPharmacies
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Cold-Chain Shipping for Compounded GLP-1sPharmacies
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Compounding Pharmacy Verification ToolTools
GLP-1 Tirzepatide Review. “Compounding Pharmacy Recalls and Warning Letters.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/pharmacies/pharmacy-recalls-warning-letters/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.